胃癌抗血管生成药物治疗的研究进展

Advances in research of antiangiogenic drugs for gastric cancer

胃癌是消化系统最常见的恶性肿瘤,居我国恶性肿瘤死亡率的第1位,传统的手术治疗和化疗预后较差.分子靶向治疗是近年来肿瘤治疗领域中的研究热点,其中抗肿瘤血管生成药物的应用在胃癌综合治疗方面取得了较大进展,包括血管内皮生长因子(vascular endothelialgrowth factor,VEGF)为靶点的单克隆抗体、可溶性受体、酪氨酸激酶受体抑制剂、血管内皮生长因子受体(vascular endothelial growthfactor receptor,VEGFR)为靶点的抗体等.

Gastric cancer is the most common cancer of the digestive system and the first leading cause of cancer deaths in China.Conventional surgery and chemotherapeutic regimens can not significantly improve the poor prognosis of gastric cancer.In recent years,molecular targeted therapy has become a hot topic in the treatment of cancers,and many antiangiogenic drugs for treatment of gastric cancer have been developed, including monoclonal antibodies or soluble receptors that bind and neutralize vascular endothelial growth factor（VEGF）,tyrosine kinase receptor inhibitors,and antibodies against VEGF receptors（VEGFRs）.